AbbVie (NYSE: ABBV) has undergone significant changes in recent years, including a leadership transition with a new CEO at the helm. While the company remains focused on biopharmaceuticals, it has successfully reduced its reliance on Humira, which previously accounted for about 37% of its total revenue.
Looking ahead, AbbVie is preparing for the expiration of Humira’s patent protection and is diversifying its product portfolio to sustain growth. The company is investing in new therapies and expanding its pipeline to mitigate the impact of increased competition on its flagship drug.
**Why this matters**
AbbVie’s ability to adapt beyond Humira is critical for maintaining its market position and revenue stability. The company’s strategic initiatives will influence its long-term growth and competitiveness in the biopharmaceutical industry.
Source: NewsData